A vaccine administered during pregnancy is significantly cutting hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a decrease of more than 80 per cent. The jab, offered to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and transferring immunity through the placenta. A significant recent study analysing nearly 300,000 births across England between September 2024 and March 2025 has demonstrated the vaccine’s “excellent protection” during the period when infants are most vulnerable to the virus. RSV affects roughly half of all newborns and remains one of the primary reasons of hospital admission in babies under one year old, with more than 20,000 serious cases recorded annually across the UK.
How the immunisation safeguards at-risk babies
RSV, or respiratory syncytial virus, is a common respiratory infection that affects approximately half of all newborns in their first few months of life. The virus can range from causing mild cold-like symptoms to triggering severe chest infections that cause babies to struggle to breathe and feed. In the most severe cases, the inflammation in the lungs becomes life-threatening, with small numbers of infants dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of severe RSV infections: “In babies with severe infections you can see their chest and lungs struggling, as they try to pull enough oxygen in. This is very, very frightening as a parent, frightening with good reason.”
The pregnancy vaccine functions by stimulating the mother’s immune system to produce protective antibodies, which are then transferred to the developing baby through the placenta. This maternal immunity offers newborns with immediate protection from the point of delivery, exactly when they are highly susceptible to RSV. The latest research shows that protection reaches approximately 85% when the vaccine is administered at least four weeks before delivery. Even shorter intervals between vaccination and birth can still deliver substantial defence, with evidence indicating that a two-week gap is sufficient to shield babies delivered prematurely. Dr Watson advises pregnant women to have the vaccine on schedule, whilst noting that protection can still occur even if given later in the third trimester.
- Nearly 85 per cent protection when immunised 4 weeks before birth
- Antibodies from the mother transferred through the placenta protect newborns from birth
- Protection achievable with 2-week gap before premature birth
- Vaccination in third trimester still provides meaningful protection for infants
Compelling evidence from the latest research
The effectiveness of the pregnancy RSV vaccine has been confirmed through a thorough investigation carried out throughout England, reviewing data from approximately 300,000 babies born between September 2024 and March 2025. This represents approximately 90% of all births during that six-month timeframe, providing strong and reliable evidence of the vaccine’s real-world impact. The study’s conclusions have been validated by the UK Health Security Agency as showing robust protection for newborns during their most critical early weeks. The scale of this research gives healthcare professionals and parents-to-be with confidence in the vaccine’s established performance across diverse populations and circumstances.
The results present a striking picture of the vaccine’s protective power. More than 4,500 babies were admitted to hospital with RSV throughout the study period, with the vast majority being infants whose mothers had not been given the vaccination. This stark contrast underscores the vaccine’s vital importance in preventing serious illness in newborns. The reduction in hospital admissions above 80 per cent represents a substantial public health milestone, helping to prevent thousands of infants from experiencing the distressing and potentially serious symptoms linked to severe RSV infection. These findings support the importance of the vaccination programme launched in the UK in 2024.
Research approach and coverage
The research analysed birth and hospital admission records from England over a six-month timeframe, capturing data on approximately 90 per cent of all births during this timeframe. By examining nearly 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were able to establish clear comparisons of RSV infection levels and hospital admissions. The sizeable sample and thorough nature of the data collection ensured that findings were statistically robust and representative of the broader population, rather than isolated cases or limited subgroups.
The study specifically tracked hospital admissions for RSV among infants born to mothers who had been given the vaccine at varying intervals before delivery. This allowed researchers to identify the least amount of time between vaccination and birth for optimal protection, as well as to determine whether protection continued to be effective with briefer timeframes. The methodology assessed real-world outcomes rather than controlled laboratory conditions, providing real-world data of how the vaccine functions when delivered across varied healthcare environments and patient circumstances throughout the final three months of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Comprehending RSV and its risks
Respiratory syncytial virus, commonly referred to as RSV, is one of the leading causes of hospitalisation in infants under one year of age across the United Kingdom. The virus affects approximately half of all newborns during their early months of life, with severity changing substantially from mild cold-like symptoms to severe, life-threatening chest infections. More than 20,000 babies require serious hospital treatment for RSV annually in the UK alone, placing considerable pressure on paediatric wards and neonatal units during peak seasons.
The infection triggers deep inflammation in the lungs and airways, making it perilously hard for infected babies to breathe and feed adequately. Parents commonly see their babies struggling visibly, their chests rising whilst they attempt to draw enough air into their damaged lungs. Whilst the majority of babies get better with supportive care, a small but significant proportion perish from RSV complications annually, making vaccination as prevention a vital health service priority for protecting the youngest and most at-risk people in our communities.
- RSV triggers lung inflammation, leading to severe breathing difficulties in infants
- Approximately half of newborns catch the virus during their first few months alive
- Symptoms vary between minor cold-like symptoms to life-threatening chest infections requiring hospitalisation
- Over 20,000 UK infants require serious hospital care for RSV each year
- A small number of infants die from RSV complications each year in the UK
Uptake rates and specialist advice
Since the RSV vaccine programme launched in 2024, health officials have highlighted the value of pregnant women receiving their jab at the best time for greatest protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has emphasised that the timing is essential for ensuring newborns receive the strongest possible immunity from birth. Whilst the study demonstrates that vaccination performed at least four weeks prior to delivery provides nearly 85% protection, experts encourage women to get their vaccine as early as possible from 28 weeks of pregnancy onwards to increase the antibodies passed to their babies through the placenta.
The messaging from health authorities remains clear: pregnant women should prioritise getting vaccinated during their final three months, even if circumstances mean they cannot get vaccinated at the optimal time. Dr Watson has reassured expectant mothers that protection is still achievable with reduced timeframes between vaccination and birth, including even a fourteen-day window for those giving birth ahead of schedule. This flexible approach recognises the practical demands of pregnancy whilst ensuring strong protection for vulnerable newborns during their most critical early months when RSV poses the greatest risk of serious illness.
Regional disparities in vaccine uptake
Whilst the RSV vaccine programme has been implemented across England, uptake rates and deployment schedules have differed across various areas and NHS trusts. Certain regions have achieved higher vaccination coverage among eligible pregnant women, whilst others continue working to boost understanding and availability of the jab. These regional differences demonstrate differences across healthcare infrastructure, engagement approaches, and community involvement initiatives, though the national data shows robust and reliable protection regardless of geographical location.
- NHS trusts rolling out multiple messaging strategies to connect with women during pregnancy
- Geographic variations in vaccination coverage levels across England necessitate strategic intervention
- Community health services tailoring initiatives to meet specific population needs
Real-world impact and parental perspectives
The vaccine’s remarkable effectiveness delivers tangible benefits for families throughout the United Kingdom. With over 20,000 babies admitted to hospital annually due to RSV before the launch of this preventative solution, the 80% reduction in admissions represents thousands of infants spared from critical disease. Parents no longer face the upsetting situation of seeing their babies labour to breathe or difficulty feeding, symptoms that define critical RSV illness. The vaccine has substantially transformed the landscape of neonatal respiratory health, offering expectant mothers a active means to protect their most vulnerable children during those critical early months.
For families like that of Malachi, whose acute RSV infection resulted in severe brain damage, the vaccine’s availability carries profound emotional significance. His mother’s advocacy for the jab highlights the life-altering consequences that preventable illness can have on young children and their families. Whilst Malachi’s experience precedes the vaccine programme, his story resonates powerfully with parents now offered protection. The knowledge that such serious complications—hospital admission, oxygen dependency, neurological damage—are now largely preventable has offered substantial reassurance to pregnant women in their late pregnancy, transforming what was once an inevitable seasonal threat into a controllable health concern.